S&P 500   3,959.58 (-0.10%)
DOW   33,690.68 (-0.27%)
QQQ   284.41 (+0.20%)
AAPL   144.11 (+1.02%)
MSFT   246.96 (-0.18%)
META   116.73 (+1.21%)
GOOGL   93.42 (-0.31%)
AMZN   89.59 (-0.84%)
TSLA   181.50 (+4.65%)
NVDA   173.32 (+0.95%)
NIO   12.86 (-4.10%)
BABA   92.32 (-1.96%)
AMD   69.64 (-1.18%)
T   19.19 (+0.37%)
MU   55.52 (+0.58%)
CGC   2.93 (-5.18%)
F   13.22 (+0.76%)
GE   82.27 (-1.63%)
DIS   93.96 (+1.52%)
AMC   5.82 (-4.12%)
PYPL   74.18 (-0.05%)
PFE   51.90 (+0.23%)
NFLX   323.76 (+4.35%)
S&P 500   3,959.58 (-0.10%)
DOW   33,690.68 (-0.27%)
QQQ   284.41 (+0.20%)
AAPL   144.11 (+1.02%)
MSFT   246.96 (-0.18%)
META   116.73 (+1.21%)
GOOGL   93.42 (-0.31%)
AMZN   89.59 (-0.84%)
TSLA   181.50 (+4.65%)
NVDA   173.32 (+0.95%)
NIO   12.86 (-4.10%)
BABA   92.32 (-1.96%)
AMD   69.64 (-1.18%)
T   19.19 (+0.37%)
MU   55.52 (+0.58%)
CGC   2.93 (-5.18%)
F   13.22 (+0.76%)
GE   82.27 (-1.63%)
DIS   93.96 (+1.52%)
AMC   5.82 (-4.12%)
PYPL   74.18 (-0.05%)
PFE   51.90 (+0.23%)
NFLX   323.76 (+4.35%)
S&P 500   3,959.58 (-0.10%)
DOW   33,690.68 (-0.27%)
QQQ   284.41 (+0.20%)
AAPL   144.11 (+1.02%)
MSFT   246.96 (-0.18%)
META   116.73 (+1.21%)
GOOGL   93.42 (-0.31%)
AMZN   89.59 (-0.84%)
TSLA   181.50 (+4.65%)
NVDA   173.32 (+0.95%)
NIO   12.86 (-4.10%)
BABA   92.32 (-1.96%)
AMD   69.64 (-1.18%)
T   19.19 (+0.37%)
MU   55.52 (+0.58%)
CGC   2.93 (-5.18%)
F   13.22 (+0.76%)
GE   82.27 (-1.63%)
DIS   93.96 (+1.52%)
AMC   5.82 (-4.12%)
PYPL   74.18 (-0.05%)
PFE   51.90 (+0.23%)
NFLX   323.76 (+4.35%)
S&P 500   3,959.58 (-0.10%)
DOW   33,690.68 (-0.27%)
QQQ   284.41 (+0.20%)
AAPL   144.11 (+1.02%)
MSFT   246.96 (-0.18%)
META   116.73 (+1.21%)
GOOGL   93.42 (-0.31%)
AMZN   89.59 (-0.84%)
TSLA   181.50 (+4.65%)
NVDA   173.32 (+0.95%)
NIO   12.86 (-4.10%)
BABA   92.32 (-1.96%)
AMD   69.64 (-1.18%)
T   19.19 (+0.37%)
MU   55.52 (+0.58%)
CGC   2.93 (-5.18%)
F   13.22 (+0.76%)
GE   82.27 (-1.63%)
DIS   93.96 (+1.52%)
AMC   5.82 (-4.12%)
PYPL   74.18 (-0.05%)
PFE   51.90 (+0.23%)
NFLX   323.76 (+4.35%)
NASDAQ:ELOX

Eloxx Pharmaceuticals - ELOX Stock Forecast, Price & News

$2.91
+0.10 (+3.56%)
(As of 12/9/2022 02:16 PM ET)
Add
Compare
Today's Range
$2.80
$2.91
50-Day Range
$0.10
$4.13
52-Week Range
$2.74
$40.40
Volume
47 shs
Average Volume
22,308 shs
Market Capitalization
$6.31 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.38

Eloxx Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
15.8% Downside
$2.38 Price Target
Short Interest
Healthy
0.87% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($18.80) to ($19.20) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.40 out of 5 stars

ELOX stock logo

About Eloxx Pharmaceuticals (NASDAQ:ELOX) Stock

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.

Receive ELOX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eloxx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ELOX Stock News Headlines

Eloxx Pharmaceuticals
ELOX Eloxx Pharmaceuticals, Inc.
Eloxx Pharmaceuticals Misses Q2 EPS by 2c
Eloxx Pharmaceuticals GAAP EPS of -$0.12 in-line
See More Headlines
Receive ELOX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eloxx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ELOX Company Calendar

Last Earnings
11/10/2022
Today
12/09/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/30/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ELOX
Employees
25
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$2.38
High Stock Price Forecast
$4.00
Low Stock Price Forecast
$1.00
Forecasted Upside/Downside
-18.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-66,730,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$10.38 per share

Miscellaneous

Free Float
1,763,000
Market Cap
$6.31 million
Optionable
Optionable
Beta
2.06

Key Executives

  • Mr. Sumit Aggarwal M.B.A. (Age 49)
    Pres, CEO & Director
    Comp: $874.7k
  • Mr. Daniel E. Geffken M.B.A.Mr. Daniel E. Geffken M.B.A. (Age 65)
    MBA, Interim CFO, Principal Financial Officer & Principal Accounting Officer
    Comp: $130.75k
  • Dr. Vijay Modur MBBS (Age 54)
    Ph.D., Head of R&D
    Comp: $648.29k
  • Ms. Barbara Ryan
    Investor Relations Officer
  • Dr. Ali Hariri M.D.
    Chief Medical Officer
  • Mr. Matthew Goddeeris Ph.D.
    VP of Research













ELOX Stock - Frequently Asked Questions

Should I buy or sell Eloxx Pharmaceuticals stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Eloxx Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ELOX shares.
View ELOX analyst ratings
or view top-rated stocks.

What is Eloxx Pharmaceuticals' stock price forecast for 2023?

2 Wall Street research analysts have issued 1-year target prices for Eloxx Pharmaceuticals' shares. Their ELOX share price forecasts range from $1.00 to $4.00. On average, they predict the company's share price to reach $2.38 in the next twelve months. This suggests that the stock has a possible downside of 15.5%.
View analysts price targets for ELOX
or view top-rated stocks among Wall Street analysts.

How have ELOX shares performed in 2022?

Eloxx Pharmaceuticals' stock was trading at $0.7062 at the start of the year. Since then, ELOX shares have increased by 297.9% and is now trading at $2.81.
View the best growth stocks for 2022 here
.

When is Eloxx Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023.
View our ELOX earnings forecast
.

How were Eloxx Pharmaceuticals' earnings last quarter?

Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) announced its quarterly earnings data on Thursday, November, 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.11) by $0.02.

What is Greg Williams' approval rating as Eloxx Pharmaceuticals' CEO?

1 employees have rated Eloxx Pharmaceuticals Chief Executive Officer Greg Williams on Glassdoor.com. Greg Williams has an approval rating of 49% among the company's employees. This puts Greg Williams in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 48.0% of employees surveyed would recommend working at Eloxx Pharmaceuticals to a friend.

What is Eloxx Pharmaceuticals' stock symbol?

Eloxx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ELOX."

Who are Eloxx Pharmaceuticals' major shareholders?

Eloxx Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.12%). Insiders that own company stock include Daniel E Geffken, Pontifax Management 4 GP (20 and Rajesh B Parekh.
View institutional ownership trends
.

How do I buy shares of Eloxx Pharmaceuticals?

Shares of ELOX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Eloxx Pharmaceuticals' stock price today?

One share of ELOX stock can currently be purchased for approximately $2.81.

How much money does Eloxx Pharmaceuticals make?

Eloxx Pharmaceuticals (NASDAQ:ELOX) has a market capitalization of $6.10 million. The company earns $-66,730,000.00 in net income (profit) each year or ($19.20) on an earnings per share basis.

How can I contact Eloxx Pharmaceuticals?

Eloxx Pharmaceuticals' mailing address is 950 WINTER STREET, WALTHAM MA, 02451. The official website for the company is www.eloxxpharma.com. The company can be reached via phone at (781) 577-5300, via email at info@eloxxpharma.com, or via fax at 908-864-4440.

This page (NASDAQ:ELOX) was last updated on 12/9/2022 by MarketBeat.com Staff